Form 4: Kura Oncology Executive Sells Shares to Cover Taxes from RSU Vesting

Thomas James Doyle, SVP of Finance & Accounting at Kura Oncology, sold a portion of his shares to cover taxes associated with the vesting of restricted stock units.

Summary

• Thomas James Doyle, the SVP of Finance & Accounting at Kura Oncology, sold a total of 4,949 shares of common stock on January 28, 2025.
• The sales were executed at a price of $7.8719 per share.
• These transactions were made to cover tax obligations arising from the vesting of previously granted restricted stock units (RSUs).
• The shares were sold in four separate transactions, with 2,241, 887, 699, and 1,122 shares sold respectively.
• Following these transactions, Mr. Doyle directly owns 88,193 shares of Kura Oncology stock and indirectly owns 500 shares through his spouse's 401(k).

Sentiment

Score: 5

Explanation: This is a routine transaction and does not indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when RSUs vest.

Comparison to Industry Standards

• The sale of shares to cover taxes from RSU vesting is a standard practice among publicly traded companies.
• Many executives at similar biotech companies regularly execute similar transactions.
• The volume of shares sold is relatively small compared to the total outstanding shares of Kura Oncology.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is unlikely to be significant.

Key Dates

Keywords

Kura Oncology, insider trading, Form 4, stock sale, restricted stock units, RSU, tax obligations, executive, Thomas James Doyle